Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085348 | 1.00 | SLC6A4 (0.48) | SLC6A4RORCMTNR1BMTNR1ACTSK | |
| SCHEMBL6084459 | 0.81 | SLC6A4 (0.56) | SLC6A4MTNR1BMTNR1A | |
| SCHEMBL6084452 | 0.81 | SLC6A4 (0.56) | SLC6A4MTNR1BMTNR1A | |
| SCHEMBL6085361 | 0.81 | SLC6A4 (0.53) | SLC6A4RORCMCHR1CNR1CNR2 | |
| SCHEMBL6084863 | 0.80 | SLC6A4 (0.57) | SLC6A4 | |
| SCHEMBL6084870 | 0.80 | SLC6A4 (0.57) | SLC6A4 | |
| SCHEMBL6084265 | 0.74 | SLC6A4 (0.56) | SLC6A4RORCCNR1CNR2HTR1A | |
| SCHEMBL6084271 | 0.74 | SLC6A4 (0.56) | SLC6A4RORCCNR1CNR2HTR1A | |
| SCHEMBL6084557 | 0.72 | SLC6A4 (0.78) | SLC6A4 | |
| SCHEMBL6084548 | 0.72 | SLC6A4 (0.78) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105516-B2 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063768-A1 | Compounds for the treatment of premature ejaculation | HTR5A, SLC18A2, CYP17A1 | SLC6A4 12/4885RORC 2310/4885MTNR1B 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.